Compare XBIO & RENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XBIO | RENX |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United States | United States |
| Employees | 2 | 6 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.3M |
| IPO Year | N/A | N/A |
| Metric | XBIO | RENX |
|---|---|---|
| Price | $3.12 | $0.14 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.8K | ★ 8.4M |
| Earning Date | 03-13-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.90 | $0.11 |
| 52 Week High | $13.93 | $0.35 |
| Indicator | XBIO | RENX |
|---|---|---|
| Relative Strength Index (RSI) | 63.53 | 46.96 |
| Support Level | $2.64 | $0.12 |
| Resistance Level | $3.60 | $0.17 |
| Average True Range (ATR) | 0.26 | 0.02 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 74.42 | 24.87 |
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
RenX Enterprises Corp is a real estate development and environmental solutions company. It is focused on the direct acquisition and indirect investment in properties across the United States that are intended for development into green single-family or multifamily housing projects. The company also focuses on the monetization of its real estate assets. It processes source-separated green waste and is expanding into the production of sustainable, high-margin potting media and soil substrates through advanced milling technology.